-0.8 C
New York
Tuesday 30 November 2021

Buy now


HomePoliticsIndiaBharat Biotech defends Covaxin after Lancet report

Bharat Biotech defends Covaxin after Lancet report

The Lancet data went against the Covaxin Phase III clinical trials' result by Bharat Biotech that had found the vaccine 77.8% effective


Reacting to a report by The Lancet, once a reputed science journal that is of late accused of politically motivated studies, which said that Covaxin is 50% effective against symptomatic Covid-19, India’s Bharat Biotech, which has developed the vaccine against the pandemic, said today that the study provided “evidence for effectiveness” of India’s first indigenous vaccine against Covid-19.

“Bharat Biotech commends the investigators from AIIMS on the BBV152 study published in (The) Lancet Infectious Diseases. These results provide evidence for effectiveness for Covaxin in real-life settings,” the vaccine manufacturer said in a statement.

The firm said, “An effectiveness result of 50% achieved during the peak Covid-19 Delta variant wave in India, in a high-risk study population of physicians and health care workers, in a health-related environment, and who are challenged repeatedly with high viral loads, provides insights into the efficacy and effectiveness of Covaxin.”

The data, published in The Lancet Infectious Diseases journal, goes against results from Bharat Biotech’s Phase III clinical trials of Covaxin, which found the vaccine to be 77.8% effective against symptomatic Covid-19. A peer review, published in the Lancet earlier this month, too, said that the shot was 77.8% effective against symptomatic infections.

A total of 2714 hospital workers at the All India Institute of Medical Sciences (AIIMS), Delhi, were assessed during this study, which took place between 15 April and 15 May, when the second Covid-19 wave was at its peak. Researchers noted that the highly infectious Delta variant was the dominant strain during the second wave, accounting for nearly 80% of all confirmed cases of coronavirus disease.

On the Delta variant, Bharat Biotech noted, “These results compare well with the 65.2 % efficacy obtained during the controlled Phase III clinical trials of Covaxin conducted among the general population.”

Covaxin, known as BBV152, was developed in collaboration with the Indian Council of Medical Research (ICMR), and is one of the two most widely-used vaccines in the national inoculation exercise. It has a two-dose regimen, with a gap of 28 days between each dose. On 3 November, it was granted Emergency Use Listing (EUL) by the World Health Organization (WHO).

Sirf News needs to recruit journalists in large numbers to increase the volume of its reports and articles to at least 100 a day, which will make us mainstream, which is necessary to challenge the anti-India discourse by established media houses. Besides there are monthly liabilities like the subscription fees of news agencies, the cost of a dedicated server, office maintenance, marketing expenses, etc. Donation is our only source of income. Please serve the cause of the nation by donating generously.

Support pro-India journalism by donating

via UPI to surajit.dasgupta@icici or

via PayTM to 9650444033

#BREAKING | July-Sept GDP expands 8.4% vs -7.4% YoY
July-Sept GVA expands 8.5% vs -7.3% YoY

#India #GDP #LIVE #Updates: https://bit.ly/3xEOe3n

করোনা পরিস্থিতির কারণে আদালতের বিচার প্রক্রিয়া চলছে হাইব্রিড মডেলে। অনেক মামলার শুনানিই চলছে অনলাইনে ভিডিয়ো কনফারেন্সের মাধ্যমে। আর তার মধ্যেই একেবারে অপ্রত্যাশিত এক ঘটনার সাক্ষী থাকল কর্নাটক হাইকোর্ট

#KarnatakaHighCourt | #TV9Bangla

The Delhi High Court declined to entertain a plea seeking a direction to the Central and #Delhi governments to ban the sale and publication of #Congress leader Salman Khurshid’s latest book.

देखें, उन देशों की लिस्ट जहां मिल चुके हैं नए कोविड -19 संस्करण के मामले

#OmicronVariant #National


Read further:

This site uses Akismet to reduce spam. Learn how your comment data is processed.

- Advertisment -



%d bloggers like this: